SEC Form 4 · accession 0000899243-16-026843
KERYX BIOPHARMACEUTICALS INC · KERX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Greg Madison
Officer — President and CEO · Director
Period of report
Aug 9, 2016
Accepted (ET)
Aug 11, 2016 · 5:45 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001114220
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Aug 9, 2016 | S | 1,622 | $4.22 | D | 257,123 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Sale of a total of 1,622 shares of common stock was made in order to satisfy Mr. Madison's income tax withholding obligation upon the vesting of 5,000 shares of restricted stock on August 8, 2016. Mr. Madison had no discretion with respect to such sale, which was transacted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock.
- F2Includes 180,687 shares of restricted stock.